Grace Cherry

发表

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

J. Sosman, A. Ribas, Douglas B. Johnson, 2016, Cell.

PD-1 blockade induces responses by inhibiting adaptive immune resistance

R. Emerson, C. Harview, A. Ribas, 2014, Nature.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

T. Graeber, T. Schumacher, B. Comin-Anduix, 2016, The New England journal of medicine.

Erratum: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (Cell (2016) 165(1) (35–44)(S009286741630215X)(10.1016/j.cell.2016.02.065))

J. Sosman, A. Ribas, Douglas B. Johnson, 2017 .

Immune Checkpoint Inhibitor-Related Adrenal Insufficiency.

Grace Cherry, 2021, Seminars in oncology nursing.

Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management

Rajan P Kulkarni, Rajan P. Kulkarni, J. Goldman, 2018, Therapeutic advances in medical oncology.

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure

T. Graeber, A. Ribas, Helena Escuin-Ordinas, 2015, Journal of Immunotherapy for Cancer.

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.

T. Graeber, L. Diaz, B. Comin-Anduix, 2017, Cancer discovery.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

J. Sosman, A. Ribas, Douglas B. Johnson, 2017, Cell.

Neoantigen-targeted CD8^+ T cell responses with PD-1 blockade therapy

O. Griffith, M. Griffith, A. Ribas, 2023, Nature.

Endocrinopathies with use of cancer immunotherapies

A. Ribas, A. Leung, M. Yeh, 2018, Clinical endocrinology.